Best Options Strategy for CRSP
Looking for the best options strategy for CRISPR Therapeutics (CRSP)? There is no single answer — the right play depends on your outlook, your risk tolerance and current implied volatility. Below, our free engine shows the highest-scoring defined-risk strategy on the live CRSP option chain right now, and a simple map from your view on CRSP to the strategy that fits it. Model any of them in the calculator before you trade.
About CRSP
CRISPR Therapeutics (CRSP) is a major company in CRISPR gene-editing therapies. Options traders on CRSP tend to watch clinical trial results, drug approvals and launches and biotech sector sentiment, since these can drive large moves in the share price.
CRSP for options traders
CRISPR Therapeutics sits at the sharp end of the gene-editing story, and its options reflect that: implied volatility runs structurally high because the company is valued largely on a pipeline of future therapies rather than on steady current earnings. With a still-narrow approved franchise, the stock lives and dies on clinical trial readouts, regulatory approvals and the pace of a new therapy launch, plus the broader mood of the biotech sector, which can lift or crush the whole cohort at once. Options on the name are liquid enough for active traders — tight-ish spreads on front-month strikes — but IV can gap higher the moment a binary catalyst appears on the horizon.
Because premium is rich, many traders lean toward selling it: iron condors, short strangles or credit spreads harvest elevated IV during the quieter stretches between catalysts, and covered calls let long holders monetise the persistent volatility. When a data readout or approval decision approaches, the playbook flips to long premium — debit call spreads, long puts or straddles that aim to capture an outsized one-day move without betting the full account. The caveat specific to this name is gap risk: a single trial or FDA headline can move the shares violently overnight, so short-premium and covered-call sellers can be run over or assigned well past their strike, and defined-risk structures are often preferred around known events.
Today's top-scoring strategy for CRSP
Our engine ranks defined-risk strategies on the live CRSP chain by probability of profit and risk/reward, then surfaces the best-scoring one. It is an educational illustration, not advice.
| Action | Qty | Type | Strike | Premium |
|---|---|---|---|---|
| Buy | 1× | CALL | $95 | $9.14 |
| Sell | 2× | CALL | $100 | $6.44 |
| Buy | 1× | CALL | $105 | $4.37 |
Simulation
Forward simulation of 6,000 lognormal price paths to expiration — not a historical backtest.
Strategy analysis
Greeks vs price
Price × volatility (today)
| −30% | −15% | IV | +15% | +30% | |
|---|---|---|---|---|---|
| $125 | −$49 | −$41 | −$37 | −$34 | −$33 |
| $120 | −$37 | −$30 | −$27 | −$26 | −$27 |
| $115 | −$19 | −$16 | −$17 | −$19 | −$22 |
| $110 | $2 | −$3 | −$8 | −$13 | −$17 |
| $105 | $20 | $8 | −$1 | −$9 | −$14 |
| $100 | $26 | $11 | $0 | −$8 | −$14 |
| $95 | $16 | $4 | −$4 | −$11 | −$17 |
| $90 | −$8 | −$11 | −$15 | −$19 | −$22 |
| $85 | −$33 | −$29 | −$28 | −$29 | −$30 |
| $80 | −$51 | −$45 | −$41 | −$39 | −$38 |
| $75 | −$60 | −$56 | −$52 | −$49 | −$47 |
Illustrative example at CRSP's latest available price, computed with the same engine as the tool. Live option fills and the real IV skew refresh during US market hours.
Implied volatility
CRSP typically trades with elevated implied volatility, so its options carry richer premiums. Implied volatility drives option prices, so it is worth checking the live chain before you trade.
Earnings & IV crush
CRSP's next earnings report is due around November 9, 2026. Options that expire after it price in a binary move, so their implied volatility is elevated and usually collapses right after the announcement — an "IV crush". If your expiration falls before this date, the trade sidesteps the event.
Key figures
- Market cap
- $5.5B
- Beta (vs market)
- 1.74
- 52-week range
- $44.12–$78.48
- Short interest
- 22.2% of float · 12.8 days to cover
With 22.2% of CRSP's float sold short, squeeze and gap risk are elevated — one reason its options can stay expensive.
How to choose an options strategy for CRSP
Start with your outlook on CRSP, then match it to a defined-risk structure. Here are the most common choices and when each makes sense:
Bullish
Buy a call for leverage with capped risk, or a bull call spread to lower the cost and breakeven when you have a target price.
Long Call → Bull Call Spread →Bearish
Buy a put to profit from a decline with defined risk, or a bear put spread to cheapen the trade when you expect a measured move down.
Long Put → Bear Put Spread →Neutral
Sell an iron condor to collect premium while CRSP stays between two strikes, or write a covered call against shares you already own.
Iron Condor → Covered Call →⧉ Embed this free calculator on your site →
How we pick the best strategy
For each ticker we pull the live option chain, build every supported strategy around the at-the-money strikes, and score them on probability of profit, risk/reward and capital efficiency — favouring defined-risk structures where the maximum loss is known up front. Methodology →
Open CRSP in the free calculator →
Frequently asked questions
What is the best options strategy for CRSP?
It depends on your outlook. Bullish traders often use a long call or bull call spread on CRSP; bearish traders a long put or bear put spread; neutral traders an iron condor or covered call. Our live scan above shows the current highest-scoring defined-risk play.
Are CRSP options liquid enough to trade?
CRISPR Therapeutics (CRSP) is among the most actively-traded US options, which usually means tight bid/ask spreads and plenty of strikes and expirations — though you should always check the open interest and spread on the exact contract.
How much money do I need to trade CRSP options?
Buying a single CRSP call or put can cost as little as the premium (often one to a few hundred dollars), while income strategies like a cash-secured put need enough capital to buy 100 shares if assigned.
Is this financial advice?
No. Everything here is educational and uses delayed, third-party data. It is not a recommendation to trade CRSP or any security. Do your own research.
What does CRISPR Therapeutics do?
CRISPR Therapeutics (CRSP) operates in the Biotechnology industry. The "About CRISPR Therapeutics" section above gives a fuller picture of what the company does and how it earns money.
Does CRISPR Therapeutics pay a dividend?
We don't show a confirmed dividend yield for CRISPR Therapeutics here, so treat it as uncertain: before writing calls, check its current dividend and ex-dividend date with your broker — an approaching ex-dividend date can trigger early assignment on in-the-money short calls.
When does CRISPR Therapeutics next report earnings?
CRISPR Therapeutics's next earnings are expected around November 9, 2026. Implied volatility usually climbs into the report and drops sharply afterwards (IV crush) — important for any options position held over the date.
Tickers related to CRSP
Comparing CRSP with similar names can help you choose the best options strategy:
Company information
- Headquarters
- Baarerstrasse 14, Zug, 6300, Switzerland
- Industry
- Biotechnology
- CEO
- Dr. Samarth Kulkarni Ph.D.
- Phone
- 41 41 561 32 77
- Website
- www.crisprtx.com
Best Options Strategy by Ticker →
Educational use only. Quotes are delayed ~15 minutes and nothing here is financial advice. Options trading involves substantial risk of loss. Privacy · Terms.